WHO recognizes that artificial intelligence (AI) holds great promise for pharmaceutical development and delivery. However, AI also presents risks and ethical challenges that must be addressed if societies, health systems and individuals are to fully reap its benefits.
A discussion paper has been developed to examine the expanding application of AI to each step of development and deployment of medicines and vaccines. AI is already used in most steps of pharmaceutical development, and, in the future, it is likely that nearly all pharmaceutical products that come to market will have been “touched” by AI at some point in their development, approval or marketing. Although these uses of AI may have a commercial benefit, it is imperative that use of AI also has public health benefit and appropriate governance.
Join this webinar to hear more about this report and to join the discussion on the benefits and challenges of the use of AI for pharmaceutical discovery and development.
Webinar
Date: Tuesday, 26 March 2024
Time: 13:00-14:00 CET
Moderator: Partha Majumder, Co-Chair, WHO Expert Group on Ethics and Goverance of AI for Health
Speakers:
- Deus Mubangizi, Director, Department of Health Products Policy and Standards, WHO
- Deirdre Dimancesco, Department of Health Products Policy and Standards, WHO
- Sameer Pujari, Department of Digital Health, WHO
- Rohit Malpani, Independent Consultant
- Sobia Raza, Head of Digital Technologies for Infectious Disease and Climate & Health, Wellcome Trust
- Michelle Childs, Policy Advocacy Director, DNDi
- Andrea Reis, Co-Head, Global Health Ethics Unit, WHO
